Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 4/20 | 0.38 |
| ▸ | DHODH | Q02127 | 5/20 | 0.37 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2922133 | 1.00 | CHRM2 (0.48) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL15437439 | 0.89 | CHRM2 (0.39) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL15437437 | 0.89 | CHRM2 (0.39) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL2924960 | 0.86 | CHRM2 (0.50) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL2927571 | 0.83 | ALDH1A1 (0.35) | DHODHMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL22801858 | 0.82 | CHRM2 (0.54) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL21680263 | 0.76 | SMN1; SMN2 (0.42) | GPR119CTSKALDH1A1MAPT | |
| SCHEMBL25010681 | 0.73 | CHRM2 (0.75) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL2123260 | 0.73 | CHRM2 (0.75) | CHRM2CHRM1CHRM3HSD11B1PREP | |
| SCHEMBL17457158 | 0.72 | ALDH1A1 (0.33) | DHODHMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2877471-B1 | SPIRO-FUSED PIPERIDINE DERIVATIVES FOR USE AS INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9206198-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150099729-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2015-04-09 | — | — | US | disclosed |
| US-8952166-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140031349-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099729-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | CHRM2 2526/4885CHRM1 2029/4885CHRM3 2282/4885 |
| US-20140031349-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | CHRM2 2526/4885CHRM1 2029/4885CHRM3 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.